Field Application Specialist - AMERICAS
Sales Specialist - North East
Sales Specialist - Mid-Atlantic
Bioproduction R&D Manager
Talk: Next-Generation Transfection Reagent for Large Scale AAV Manufacturing
Transient transfection of suspension cells is the most commonly used production platform for AAV manufacturing.
However, this method shows some limitations in large scale bioreactors: inadequate transfection protocol, reduced transfection efficiency and lower productivity. To address this concern, we present data on the novel transfection reagent showing: i) increased AAV titers, ii) improved transfection protocol for large scale bioreactors and iii) reproducibility of viral titers at different production scale.
Presented by Mathieu Porte, R&D Production Manager at Polyplus-transfection®
Talk Available on demande on the In Vivo Gene Therapy track for the duration of the virtual event
Our solutions for both protein and virus production
NEW! FectoVIR®-AAV: for Recombinant AAV virus production in suspension cells.
PEIpro® product range for a scalable viral vector production for Gene & Cell therapy.